Table 3.
Univariate and multivariate Cox regression analysis of the factors predicting cancer-specific survival.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Total patients | ||||
| Age (years) | 0.982 (0.955–1.008) | 0.175 | ||
| PSA level at surgery (ng/mL) | 1.002 (1.001–1.004) | 0.007 | 1.002 (1.000–1.003) | 0.046 |
| Testosterone level at surgery (ng/mL) | 0.520 (0.307–0.882) | 0.015 | 0.666 (0.397–1.119) | 0.125 |
| Gleason score | <0.001 | 0.011 | ||
| 8 vs. 7 | 3.346 (0.722–15.510) | 0.123 | 6.384 (1.168–36.953) | 0.032 |
| 9 vs. 7 | 8.827 (2.098–37.133) | 0.003 | 7.358 (1.569–41.238) | 0.019 |
| 10 vs. 7 | 14.555 (3.308–64.035) | <0.001 | 13.231 (2.652–72.194) | 0.002 |
| Distant metastasis | 11.247 (4.000–31.623) | <0.001 | 5.291 (2.235–23.822) | 0.001 |
| ARfl (High vs. Low) | 1.923 (1.141–3.240) | 0.014 | 1.638 (0.895–3.159) | 0.102 |
| ARV7 (High vs. Low) | 2.041 (1.174–3.548) | 0.011 | 1.238 (0.953–4.328) | 0.078 |
| GR (High vs. Low) | 1.787 (1.009–3.165) | 0.047 | 0.953 (0.398–1.890) | 0.725 |
| Patients with castration-resistant prostate cancer | ||||
| Age (years) | 1.001 (0.966–1.037) | 0.962 | ||
| PSA level at surgery (ng/mL) | 1.002 (1.001–1.004) | 0.008 | 1.002 (1.000–1.005) | 0.028 |
| Testosterone level at surgery (ng/mL) | 2.483 (0.837–7.361) | 0.101 | ||
| Gleason score | 0.126 | 0.106 | ||
| 9 vs. 8 | 3.973 (0.895–17.640) | 0.070 | 3.847 (0.798–16.824) | 0.097 |
| 10 vs. 8 | 4.933 (1.059–22.973) | 0.042 | 4.982 (1.107–24.128) | 0.038 |
| Distant metastasis | 3.923 (0.883–17.422) | 0.072 | ||
| ARfl (High vs. Low) | 1.852 (0.951–3.606) | 0.070 | ||
| ARV7 (High vs. Low) | 2.032 (1.163–3.782) | 0.020 | 1.897 (1.102–3.625) | 0.042 |
| GR (High vs. Low) | 0.838 (0.450–1.559) | 0.576 | ||
Statistically significant values are indicated in bold.
HR, hazard ratio; CI, confidence interval; ARfl, androgen receptor full length; ARV7, androgen receptor splice variant 7; GR, glucocorticoid receptor.